

ASX Release**Oventus receives \$417k R&D tax incentive refund for FY21**

- **Cash refund of \$417k received for the FY21 financial year**
- **R&D tax incentive is an important ongoing source of non-dilutive funding for Oventus**

Brisbane, Australia 28 January 2022: Obstructive Sleep Apnea (OSA) therapeutics company, Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce that it has received a cash refund of \$417k from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The refund is from FY2021 research activities which yielded significant product outcomes across the Company's Sleep Treatment Platform.

CEO, Dr Chris Hart commented, "The R&D tax incentive provides Oventus with a valuable non-dilutive source of funding support. We are grateful to have the ongoing support of the Australian Federal Government's tax incentive program which assists us with bringing our innovative sleep apnea therapeutics to market."

—ENDS—

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus Medical's mission is to be a global leader in the management of sleep-disordered breathing, by providing a seamless patient journey and innovative oral appliance therapies. Oventus' Obstructive Sleep Apnea (OSA) treatment, called the O2Vent, has been demonstrated to be more effective and more desirable than other treatment options, offering hope for discreet, comfortable and effective relief to millions of people suffering from OSA. Based in Brisbane, Australia and Irvine, California, the company has extensive clinical data demonstrating that its platform, with integrated airway support, has the potential to be accepted as a preferred first-line therapy for patients with mild to moderate sleep apnea.

In order to become the first choice for patients and clinicians alike, Oventus also makes the process for entering OSA treatment efficient, engaging and convenient. Oventus and its clinical partners have developed a virtual consultation and fitting process that enables patients to receive their custom-fit device and initiate

O2Vent®



therapy from the comfort of their home, all while maintaining the highest standards of service and patient care. By developing a complete solution, from best-in-class technology to outstanding care, Oventus has raised the bar for Sleep Apnea treatments in a rapidly-growing US\$31B addressable market.